News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
|Articles|November 1, 2003

Pharmaceutical Executive

  • Pharmaceutical Executive-11-01-2003

Table of Contents

Table of Contents

Advertisement
External Link - article-75642.pdf

Articles in this issue

over 22 years ago

Article

The Ten Billion Dollar Molecule

over 22 years ago

Article

The Path to Smart R&D

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher

ByNicholas Jacobus
April 29th 2026
Stock.adobe.com global drug supply

Pharmaceutical Risks in the Strait of Hormuz

ByGeralyn Ritter,Monica Gorman, PhD
April 29th 2026
Stock.adobe.com deal

Teva Enters $900 Million Agreement to Acquire Emalex

ByNicholas Jacobus
April 29th 2026
Kim Plesnarski,  Syneos Health

Asembia's AXS26 Summit: Q&A with Kim Plesnarski

ByNicholas Jacobus,Kim Plesnarski
April 29th 2026
Stock.adobe.com Sale

Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher

ByNicholas Jacobus
April 29th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market

2

Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?

3

Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs

4

How are US Regulatory Actions Impacting Pricing?

5

Pharmaceutical Risks in the Strait of Hormuz

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us